PLAY PODCASTS
Rick Doblin on Sending the Soviets MDMA, Treating PTSD with Psychedelics and What the Future Holds
Episode 72

Rick Doblin on Sending the Soviets MDMA, Treating PTSD with Psychedelics and What the Future Holds

Rick Doblin is the Executive Director and Founder of MAPS, the Multidisciplinary Association of Psychedelic Studies. In this episode, he and James Hallifax discuss MAPS’ work treating PTSD with MDMA, sending the Soviets Psychedelics, and what the future holds.

Psychedelic Spotlight Podcast · Rick Doblin, The Psychedelic Investor, Global Trac Solutions Inc., Psychedelic Spotlight, MAPS, James Hallifax

January 26, 202251m 21s

Audio is streamed directly from the publisher (cdn.simplecast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Over the last several decades, Rick Doblin and his organization, MAPS, have been at the forefront of changing cultural attitudes surrounding psychedelics. They have accomplished this through several avenues. 

The first is researching the medical applications of psychedelics. Most prominently, they have been testing treating severe PTSD with MDMA-assisted therapy, the results of which have been amazing. For example, in their most recent phase 3 clinical trial, 67% of patients with severe PTSD improved so much they no longer qualified for the diagnosis of PTSD. In this interview, James and Rick discuss this trial and upcoming follow-up trials.

MAPS has also been involved in extensive psychedelic education campaigns. Their newest endeavor is a “psychonaut training program”, which will teach regular people how to “trip” properly, and how to be a trip sitter.

Finally, James and Rick discuss his wild plan in the 80s to send MDMA to the Soviet Union in an attempt to make nuclear negotiators more empathetic. 

Join us on this amazing journey.

Topics

mdmapsychedelic-assisted psychotherapypsychotherapistpsychotherapymeditationmushroomsshroomsrick doblinmagic shroomsbusinessmental healthmdma-assisted therapyhealthclinical trialspsilocybinlsdmapsplant medicinepsychedelics